![Adipogen/Ixazomib citrate [MLN9708]/AG-CR1-3671-M001/1 mg](https://www.ebiomall.cn/images/adipogen/ag-cr1-3671.png)
Adipogen/Ixazomib citrate [MLN9708]/AG-CR1-3671-M001/1 mg
商品编号:
AG-CR1-3671-M001
品牌:
Adipogen Inc
市场价:
¥700.00
美元价:
420.00
产品分类:
其他试剂
公司分类:
Other_reagents
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
ProductDetails | |
---|---|
Synonyms | (R)-2,2"-(2-(1-(2-(2,5-Dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diaceticacid |
ProductType | Chemical |
Properties | |
Formula | C20H23BCl2N2O9 |
MW | 517.1 |
CAS | 1239908-20-3 |
PurityChemicals | ≥98% |
Appearance | Whitesolid. |
Solubility | SolubleinDMSO(5mg/ml)orDMF(5mg/ml).Poorlysolubleinaqueousbuffers. |
OtherProductData | Note:Warmingandsonicationmayberequiredwhendissolvingthecompoundinthesolventofchoice.Stocksolutionsarestableforatleast1monthwhenstoredat-20°C. |
InChiKey | MBOMYENWWXQSNW-AWEZNQCLSA-N |
ShippingandHandling | |
Shipping | AMBIENT |
ShortTermStorage | +4°C |
LongTermStorage | -20°C |
HandlingAdvice | Keepcoolanddry. |
Use/StABIlity | Stableforatleast2yearsafterreceiptwhenstoredat-20°C. |
Documents | |
MSDS | ![]() |
ProductSpecificationSheet | |
Datasheet | ![]() |
- PotentselectiveandreversIBLeproteasomeinhibitor(allproteolyticsubunits).
- Targetsthechymotrypsin-likeβ5subunitoftheconstitutive20Sproteasome(IC50=3.4nM).Cross-reactsandinhibitsthetrypsin-likeβ2subunit(IC50=3.5μM)andthecaspase-like/peptidyl-glutamylpeptide-hydrolyzing(PGPH)β1subunit(IC50=0.03μM).
- Anticancercompoundeffectiveincell-basedassays,inxenograftsandagainstmultiplemyelomainvivo.
- Invitro,inducescellcyclearrestandapoptosisinhumancancercelllinesincludingmultiplemyeloma.
- ProdrugthatrapidlyhydrolyzestoMLN2238(Prod.No.AG-CR1-3670).
- Exhibitsimprovedpharmacodynamicsandantitumoractivitycomparedtobortezomib(Prod.No.AG-CR1-3602)invariousBcelllymphomamodels,duetoagreatertumortobloodratioofproteasomeinhibitionthatultimatelytranslatesintoimprovedtumorpharmacodynamicresponseandantitumoractivityinseveraltumorxenograftmodels.
ProductReferences
- EvaluationoftheproteasomeinhibitorMLN9708inpreclinicalmodelsofhumancancer:E.Kupperman,etal.;CancerRes.70,1970(2010)
- InvitroandinvivoselectiveantitumoractivityofanovelorallybioavailableproteasomeinhibitorMLN9708againstmultiplemyelomacells:D.Chauhan,etal.;Clin.CancerRes.17,5311(2011)
- AntitumoractivityoftheinvestigationalproteasomeinhibitorMLN9708inmousemodelsofB-cellandplasmacellmalignancies:E.C.Lee,etal.;Clin.CancerRes.17,7313(2011)
- InvestigationalagentMLN9708/2238targetstumor-suppressormiR33binMMcells:Z.Tian,etal.;Blood120,3958(2012)
- MLN2238,aproteasomeinhibitor,inducescaspase-dependentcelldeath,cellcyclearrest,andpotentiatesthecytotoxicactivityofchemotherapyagentsinrituximab-chemotherapy-sensitiveorrituximab-chemotherapy-resistantB-celllymphomapreclinicalmodels:J.J.Gu,etal.;AnticancerDrugs24,1030(2013)
- PreclinicalactivityoftheoralproteasomeinhibitorMLN9708inMyelomabonedisease:A.Garcia-Gomez,etal.;Clin.CancerRes.20,1542(2014)
- TheinvestigationalagentMLN2238inducesapoptosisandiscytotoxictoCLLcellsinvitro,asasingleagentandincombinationwithotherdrugs:A.Paulus,etal.;Br.J.Haematol.165,78(2014)
- Anevidence-basedreviewofixazomibcitrateanditspotentialinthetreatmentofnewlydiagnosedmultiplemyeloma:M.Offidani,etal.;Onco.TargetsTher.7,1793(2014)
- Theinvestigationalproteasomeinhibitorixazomibforthetreatmentofmultiplemyeloma:P.G.Richardson,etal.;FutureOncol.11,1153(2015)
- ComparisonofantiproliferativeandapoptoticeffectsofanovelproteasomeinhibitorMLN2238withbortezomibonK562chronicmyeloidleukemiacells:S.Engur,etal.;Immunopharmacol.Immunotoxicol.38,87(2016)
- ProteasomalInhibitionbyIxazomibInducesCHK1andMYC-DependentCellDeathinT-cellandHodgkinLymphoma:D.Ravi,etal.;CancerRes.76,3319(2016)
- Thepotentialofixazomib,asecond-generationproteasomeinhibitor,inthetreatmentofmultiplemyeloma:J.Brayer&R.Baz;Ther.Adv.Hematol.8,209(2017)(Review)
品牌介绍
Adipogen公司由三个子公司组成,分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国,运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发,如癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外,也可提供抗体和蛋白产品,Adipogen拥有自己的化学实验室,致力于开发创新型小分子化合物。
联络我们